Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Gains from Sales and Divestitures (2023 - 2025)

Maxcyte (MXCT) reported Gains from Sales and Divestitures of $609460.0 for Q4 2025, up 45.71% year-over-year from $418260.0 in Q4 2024, and up 45.71% on a QoQ basis from $418260.0 in Q4 2024.

Maxcyte (MXCT) has 3 years of Gains from Sales and Divestitures data on file, last reported at $609460.0 in Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 45.71% year-over-year to $609460.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $609460.0 (up 45.71% YoY) and the FY2025 annual result came in at $609460.0, up 45.71% from the prior year.
  • Gains from Sales and Divestitures grew to $609460.0 in Q4 2025 per MXCT's latest filing, from $418260.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $609460.0 in Q4 2025 and bottomed at $288550.0 in Q4 2023.
  • The 3-year median for Gains from Sales and Divestitures is $418260.0 (2024), against an average of $438756.7.
  • The widest annual swing landed in 2024, when Gains from Sales and Divestitures jumped 44.95%; it then jumped 45.71% in 2025.
  • Tracing MXCT's Gains from Sales and Divestitures over 3 years: stood at $288550.0 in 2023, then jumped by 44.95% to $418260.0 in 2024, then soared by 45.71% to $609460.0 in 2025.
  • Per Business Quant, the three latest MXCT Gains from Sales and Divestitures figures stand at $609460.0 (Q4 2025), $418260.0 (Q4 2024), and $288550.0 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Maxcyte 129.85 Mn 129.85 Mn 8.08 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 609,460.00
Dec 31, 2025 609,460.00
Dec 31, 2024 418,260.00
Dec 31, 2024 418,260.00
Dec 31, 2023 288,550.00
Dec 31, 2023 288,550.00